Monte Rosa Therapeutics swings to Q3 net income of $3.06 million from year-earlier loss
Bitget2026/11/05 12:14- Monte Rosa Therapeutics swung to third-quarter 2026 net income of $3.06 million from a year-earlier net loss of $27.08 million.
- Collaboration revenue rose year-over-year to $54.37 million, primarily driven by a $50 million milestone for Novartis’s Sjögren’s disease study initiation.
- Cash, cash equivalents, restricted cash and marketable securities totaled $582.6 million at September 30, expected to support operations into 2029.
- MRT-8102’s Phase 2 gout study is expected to begin in Q4 2026, with initial data anticipated in H2 2027.
- The Phase 2 MODeFIRe-1 prostate cancer study began dosing in August, with a clinical data update expected in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
